Tyme Technologies, Inc., a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-461-2315
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
OptionableOptionable
Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions
What is Tyme Technologies' stock symbol?
Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."
How were Tyme Technologies' earnings last quarter?
Tyme Technologies Inc (NASDAQ:TYME) posted its quarterly earnings results on Monday, November, 5th. The company reported ($0.07) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.08) by $0.01. View Tyme Technologies' Earnings History.
When is Tyme Technologies' next earnings date?
What price target have analysts set for TYME?
2 Wall Street analysts have issued 1-year price objectives for Tyme Technologies' shares. Their predictions range from $10.00 to $10.00. On average, they anticipate Tyme Technologies' stock price to reach $10.00 in the next year. This suggests a possible upside of 168.1% from the stock's current price. View Analyst Price Targets for Tyme Technologies.
What is the consensus analysts' recommendation for Tyme Technologies?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tyme Technologies.
What are Wall Street analysts saying about Tyme Technologies stock?
Here are some recent quotes from research analysts about Tyme Technologies stock:
- 1. According to Zacks Investment Research, "Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize in the body's immune system to treat diseases. Tyme Technologies, Inc. is headquartered in New York. " (1/10/2019)
- 2. HC Wainwright analysts commented, "We maintain our Buy rating of TYME and our 12-month price target of $9.50 per share. We derive our price target based on a net present value analysis of projected SM-88 revenues through FY2030 assuming a 12% discount rate and 2% terminal growth rate." (11/7/2018)
- 3. Canaccord Genuity analysts commented, "We continue to view SM-88’s ability to generate responses across ~15 solid and liquid tumor types and with durable effect in advanced cancer patients progressing on available therapies as intriguing and reiterate our BUY rating." (6/15/2018)
Has Tyme Technologies been receiving favorable news coverage?
Media stories about TYME stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tyme Technologies earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
Are investors shorting Tyme Technologies?
Tyme Technologies saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 7,718,246 shares, an increase of 103.7% from the December 14th total of 3,789,460 shares. Based on an average daily volume of 1,496,507 shares, the short-interest ratio is currently 5.2 days. Currently, 19.3% of the company's shares are short sold. View Tyme Technologies' Current Options Chain.
Who are some of Tyme Technologies' key competitors?
Some companies that are related to Tyme Technologies include Biohaven Pharmaceutical (BHVN), Enanta Pharmaceuticals (ENTA), Cambrex (CBM), Aimmune Therapeutics (AIMT), Arrowhead Pharmaceuticals (ARWR), Nabriva Therapeutics (NBRV), Phibro Animal Health (PAHC), Wave Life Sciences (WVE), Myovant Sciences (MYOV), TherapeuticsMD (TXMD), Clovis Oncology (CLVS), Uniqure (QURE), Esperion Therapeutics (ESPR), Kiniksa Pharmaceuticals (KNSA) and Spectrum Pharmaceuticals (SPPI).
Who are Tyme Technologies' key executives?
Tyme Technologies' management team includes the folowing people:
- Mr. Steven E. Hoffman, Co-Founder, Chairman, CEO & Chief Science Officer (Age 55)
- Mr. Ben R. Taylor, Pres & CFO (Age 41)
- Mr. Michael S. Demurjian, Exec. VP, COO & Director (Age 51)
- Dr. Jonathan M. Eckard, Chief Scientific Affairs Officer (Age 44)
- Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 54)
How do I buy shares of Tyme Technologies?
Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tyme Technologies' stock price today?
One share of TYME stock can currently be purchased for approximately $3.73.
How big of a company is Tyme Technologies?
Tyme Technologies has a market capitalization of $361.17 million. The company earns $-18,960,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.
What is Tyme Technologies' official website?
How can I contact Tyme Technologies?
Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]
MarketBeat Community Rating for Tyme Technologies (NASDAQ TYME)
MarketBeat's community ratings are surveys of what our community members think about Tyme Technologies and other stocks. Vote "Outperform" if you believe TYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TYME will underperform the S&P 500 over the long term. You may vote once every thirty days.
